Increased protein processing gene signature in HDACi-resistant cells predicts response to proteasome inhibitors.

about

Increased protein processing gene signature in HDACi-resistant cells predicts response to proteasome inhibitors.

Item

http://www.wikidata.org/entity/Q52869149

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年学术文章

@wuu

2016年学术文章

@zh

2016年学术文章

@zh-cn

2016年学术文章

@zh-hans

2016年学术文章

@zh-my

2016年学术文章

@zh-sg

2016年學術文章

@yue

2016年學術文章

@zh-hant

name

Increased protein processing g ...... onse to proteasome inhibitors.

@en

Increased protein processing g ...... onse to proteasome inhibitors.

@nl

type

Item

label

Increased protein processing g ...... onse to proteasome inhibitors.

@en

Increased protein processing g ...... onse to proteasome inhibitors.

@nl

prefLabel

Increased protein processing g ...... onse to proteasome inhibitors.

@en

Increased protein processing g ...... onse to proteasome inhibitors.

@nl

P1476

Increased protein processing g ...... onse to proteasome inhibitors.

@en

P2093

Cynthia Guilbert

http://www.w3.org/2001/XMLSchema#string

Dany Plourde

http://www.w3.org/2001/XMLSchema#string

Daphné Dupéré-Richer

http://www.w3.org/2001/XMLSchema#string

Filippa Pettersson

http://www.w3.org/2001/XMLSchema#string

Jessica N Nichol

http://www.w3.org/2001/XMLSchema#string

Jonathan D Licht

http://www.w3.org/2001/XMLSchema#string

Kathleen Klein Oros

http://www.w3.org/2001/XMLSchema#string

Koren K Mann

http://www.w3.org/2001/XMLSchema#string

M Nieves Calvo-Vidal

http://www.w3.org/2001/XMLSchema#string

Mena Kinal

http://www.w3.org/2001/XMLSchema#string

P2860

Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in patients with advanced hematologic malignancies.

Phase II trial of oral vorinostat (suberoylanilide hydroxamic acid) in relapsed diffuse large-B-cell lymphoma.

Phase Ib study of panobinostat and bortezomib in relapsed or relapsed and refractory multiple myeloma.

A multicentre phase II study of vorinostat in patients with relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma

The pan-HDAC inhibitor vorinostat potentiates the activity of the proteasome inhibitor carfilzomib in human DLBCL cells in vitro and in vivo

Carfilzomib interacts synergistically with histone deacetylase inhibitors in mantle cell lymphoma cells in vitro and in vivo

Mechanisms of epigenetic deregulation in lymphoid neoplasms.

Efficacious proteasome/HDAC inhibitor combination therapy for primary effusion lymphoma.

The mammalian endoplasmic reticulum-associated degradation system

Mechanism-based epigenetic chemosensitization therapy of diffuse large B-cell lymphoma.

P304

218-221

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1080/10428194.2016.1180684

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Leandro Cerchietti

Audrey Emond

P577

2016-05-17T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27185211

http://www.w3.org/2001/XMLSchema#string